Flatiron Health

factnew Flatiron Health remains a wholly-owned, independently-operated affiliate of Roche Group (acquired April 2018 for ~$1.9B), with no full sale completed as of December 2025 despite a 2024 Roche-led exploration.

factnew On 2025-12-04 Paradigm Health (ARCH-incubated) acquired Flatiron's Clinical Research Business — its tech-enabled US oncology trial network (~100 community practices, 2.4M+ patients) and clinical-research solutions — while Flatiron retained OncoEMR and its real-world data/evidence business.

factnew Independent reporting indicates Roche ownership has deterred rival drugmakers from buying Flatiron data and hurt sales, with ~two-thirds of Flatiron revenue coming from pharma data sales — the dynamic behind Roche's 2024 Citigroup-advised sale exploration.

factnew Flatiron's US real-world database spans 5M+ patient records across 200+ oncology practices and 1,000+ sites of care (~70% community, ~30% academic) covering 22+ tumor types, combining structured EHR fields with human-abstracted unstructured notes, pathology and radiology.

factnew In March 2025 Flatiron tripled its global oncology research network to 30+ sites, enabling patient-level real-world data sharing across four countries (US, UK, Germany, Japan) — a geographic expansion that remains entirely within oncology.

factnew The Flatiron-Foundation Medicine Clinico-Genomic Database links Flatiron EHR-derived clinical data to FMI comprehensive genomic profiling (~600 cancer-related genes from 400,000+ samples across ~280 clinics) and underpins 100+ publications, but both partners are now Roche-owned, making it an intra-Roche multimodal asset.

factnew Flatiron has maintained a standing FDA Research Collaboration Agreement since 2016 (publicly renewed/expanded in 2019) to validate real-world endpoints — progression, tumor response, discontinuation — and explore real-world control arms; no fresh 2025-2026 renewal is independently confirmed.

factnew RWE from the Flatiron Health Analytic Database supported the 2019 FDA label expansion of palbociclib (Ibrance) to male metastatic breast cancer via a supplemental NDA, while FDA simultaneously flagged the chart-review data's selection bias, confounding and limited generalizability.

factnew Flatiron states (company-reported, undated) it has received FDA, EMA and PMDA feedback on the utility of its real-world data across 22 unique submission opportunities with more than a dozen biopharma partners.

factnew Flatiron launched Flatiron Telescope on 2026-05-19, an AI platform that translates natural-language criteria into patient cohorts and assesses study feasibility in real time for non-technical life-sciences users.

factnew In February 2026 Flatiron launched 'Panoramic' AI-powered global prostate-cancer datasets for the UK and Germany (~400,000 patients across US/UK/Germany), with breast and non-small-cell lung cancer datasets planned for 2027.

factnew Flatiron monetizes a two-sided model — OncoEMR cloud EHR across 280+ community oncology clinics (~800 sites) feeding tech-enabled human-abstracted research-grade datasets licensed to pharma — and since 2023 has layered on 'Integrated RWE Solutions' end-to-end services from early development through commercialization.

factnew Flatiron's 23 open roles (June 2026, Greenhouse) are overwhelmingly oncology (21/23) with zero cardiology, neurology or immunology postings despite active hiring, and span international offices (London, Berlin, Tokyo, Durham) — confirming oncology concentration plus geographic, not therapeutic, expansion.

factnew Flatiron real-world data underpins a high volume of 2025-2026 peer-reviewed oncology RWE (82 PubMed records since Jan 2025) built on real-world PFS/OS-style endpoints, and Flatiron published its own VALID framework (JCO Clinical Cancer Informatics, 2026) to validate the accuracy of LLM/ML-extracted EHR data.

factnew At least 12 pharma-sponsored real-world/observational oncology studies registered on ClinicalTrials.gov since January 2025 specify the 'Flatiron Health database' as their data source (spanning metastatic bladder, prostate, HER2+ breast, colorectal, melanoma and multiple myeloma), evidencing active sponsor adoption for real-world outcomes.

factnew Nathan Hubbard — previously head of Flatiron's international business — became CEO on 2025-08-06, succeeding Carolyn Starrett (CEO since 2021, now senior advisor), alongside new CBO Michael Bierl, CTO Allison Candido and CPO Kate Estep, under a stated strategy to build an 'integrated global platform.'

factnew Flatiron Health remains a wholly-owned, independently-operated affiliate of Roche Group (acquired April 2018 for ~$1.9B), with no full sale completed as of December 2025 despite a 2024 Roche-led exploration.

factnew On 2025-12-04 Paradigm Health (ARCH-incubated) acquired Flatiron's Clinical Research Business — its tech-enabled US oncology trial network (~100 community practices, 2.4M+ patients) and clinical-research solutions — while Flatiron retained OncoEMR and its real-world data/evidence business.

factnew Independent reporting indicates Roche ownership has deterred rival drugmakers from buying Flatiron data and hurt sales, with ~two-thirds of Flatiron revenue coming from pharma data sales — the dynamic behind Roche's 2024 Citigroup-advised sale exploration.

factnew Nathan Hubbard — previously head of Flatiron's international business — became CEO on 2025-08-06, succeeding Carolyn Starrett (CEO since 2021, now senior advisor), alongside new CBO Michael Bierl, CTO Allison Candido and CPO Kate Estep, under a stated strategy to build an 'integrated global platform.'

factnew Flatiron's US real-world database spans 5M+ patient records across 200+ oncology practices and 1,000+ sites of care (~70% community, ~30% academic) covering 22+ tumor types, combining structured EHR fields with human-abstracted unstructured notes, pathology and radiology.

factnew In March 2025 Flatiron tripled its global oncology research network to 30+ sites, enabling patient-level real-world data sharing across four countries (US, UK, Germany, Japan) — a geographic expansion that remains entirely within oncology.

factnew The Flatiron-Foundation Medicine Clinico-Genomic Database links Flatiron EHR-derived clinical data to FMI comprehensive genomic profiling (~600 cancer-related genes from 400,000+ samples across ~280 clinics) and underpins 100+ publications, but both partners are now Roche-owned, making it an intra-Roche multimodal asset.

factnew Flatiron launched Flatiron Telescope on 2026-05-19, an AI platform that translates natural-language criteria into patient cohorts and assesses study feasibility in real time for non-technical life-sciences users.

factnew In February 2026 Flatiron launched 'Panoramic' AI-powered global prostate-cancer datasets for the UK and Germany (~400,000 patients across US/UK/Germany), with breast and non-small-cell lung cancer datasets planned for 2027.

factnew Flatiron monetizes a two-sided model — OncoEMR cloud EHR across 280+ community oncology clinics (~800 sites) feeding tech-enabled human-abstracted research-grade datasets licensed to pharma — and since 2023 has layered on 'Integrated RWE Solutions' end-to-end services from early development through commercialization.

factnew Flatiron has maintained a standing FDA Research Collaboration Agreement since 2016 (publicly renewed/expanded in 2019) to validate real-world endpoints — progression, tumor response, discontinuation — and explore real-world control arms; no fresh 2025-2026 renewal is independently confirmed.

factnew RWE from the Flatiron Health Analytic Database supported the 2019 FDA label expansion of palbociclib (Ibrance) to male metastatic breast cancer via a supplemental NDA, while FDA simultaneously flagged the chart-review data's selection bias, confounding and limited generalizability.

factnew Flatiron states (company-reported, undated) it has received FDA, EMA and PMDA feedback on the utility of its real-world data across 22 unique submission opportunities with more than a dozen biopharma partners.

factnew Flatiron real-world data underpins a high volume of 2025-2026 peer-reviewed oncology RWE (82 PubMed records since Jan 2025) built on real-world PFS/OS-style endpoints, and Flatiron published its own VALID framework (JCO Clinical Cancer Informatics, 2026) to validate the accuracy of LLM/ML-extracted EHR data.

factnew At least 12 pharma-sponsored real-world/observational oncology studies registered on ClinicalTrials.gov since January 2025 specify the 'Flatiron Health database' as their data source (spanning metastatic bladder, prostate, HER2+ breast, colorectal, melanoma and multiple myeloma), evidencing active sponsor adoption for real-world outcomes.

factnew Flatiron's 23 open roles (June 2026, Greenhouse) are overwhelmingly oncology (21/23) with zero cardiology, neurology or immunology postings despite active hiring, and span international offices (London, Berlin, Tokyo, Durham) — confirming oncology concentration plus geographic, not therapeutic, expansion.